Drug Trial Radar · NCT05753930
Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jun 2, 2023
Primary completion
Feb 28, 2027
Study completion Aug 31, 2031
Sponsor
- Lead sponsor
- Hansa Biopharma ABIndustry
- Sponsor type
- Industry
- First posted
- Mar 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD). The main questions it aims to answer are: * Does imlifidase treatment result in crossmatch conversion that enables transplantation? * How is the function of the transplanted kidney? The participants will be hospitalised in accordance with the normal routines for transplanted patients. The patients will receive medication to prevent rejection of the donor kidney, and because such treatment make the body more vulnerable medications to prevent infections.
Conditions
- Kidney Transplantation in Highly Sensitized Patients
Interventions
ImlifidaseDrug
Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with conversion of a positive crossmatch test to negative within 24 hours after start of imlifidase treatmentTime frame: From start of imlifidase administration to 24 hours
Locations
7 sites in 6 countries. Site status is shown where the registry gives one.
HUS, Helsinki University Hospital
Helsinki, Finland · Withdrawn
Robert Debre University Hospital
Paris, France · Recruiting
Ospedale Pediatrico Bambino Gesu
Rome, Italy · Not yet recruiting
Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica
Barcelona, Spain · Recruiting
Hospital Sant Joan De Deu Barcelona
Barcelona, Spain · Not yet recruiting
Karolinska University Hospital
Huddinge, Stockholm County, Sweden · Recruiting
Great Ormond Street Hospital for Children NHS Foundation Trust
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.